Ceribell CRO Joseph Manni Sells $32,691 in Shares
0h ago|5 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
ceribellinsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. AiX is informational software — not investment advice. Past performance does not guarantee future results.
Ceribell Chief Revenue Officer Joseph Manni sold shares worth $32,691 according to a filing reported on August 26, 2026. The transaction occurred as Ceribell stock traded at $23.95, representing a daily decline of 1.03% from the previous session's close. Trading volume patterns and price movements around insider sales provide measurable data points for institutional analysis of executive confidence and stock liquidity conditions.
Insider transactions require disclosure within two business days under SEC Regulation 16b-3, providing timely signals for market participants. The current transaction follows a pattern of increased insider activity across healthcare technology stocks in August 2026. The healthcare equipment sector has shown elevated volatility compared to broader market indices, with the iShares U.S. Medical Devices ETF (IHI) declining 2.3% month-to-date through August 25.
Federal Reserve policy remains a key backdrop for growth stocks like Ceribell, with the target federal funds rate at 4.25-4.50% as of the July 2026 meeting. Higher financing costs pressure medical technology companies that rely on capital investment for research and development expansion. The sector faces additional scrutiny from Medicare reimbursement reviews scheduled for Q4 2026.
Ceribell specializes in portable electroencephalography devices for rapid seizure detection, a market segment that grew 18% annually from 2023 to 2025 according to MedTech Industry Reports. The company's second-quarter earnings on August 15, 2026 showed revenue growth of 22% year-over-year but missed analyst expectations by 3%. This earnings miss preceded the current insider transaction by eleven calendar days.
Previous insider sales at Ceribell show a pattern of executive transactions following quarterly earnings releases. Chief Technology Officer David Wang sold $41,200 in shares on May 17, 2026, two days after Q1 earnings. That transaction preceded a 5.2% stock decline over the subsequent ten trading sessions. The current sale follows a similar post-earnings timing pattern observed in previous quarters.
Ceribell shares traded at $23.95 as of 00:16 UTC today, representing a 1.03% decline from the previous closing price. The stock reached an intraday low of $23.65 and high of $24.24 during the session, creating a trading range of $0.59. Volume data shows 423,000 shares traded compared to the 30-day average volume of 387,000 shares, indicating 9% above average trading activity.
| Metric | Value |
|---|---|
| Current Price | $23.95 |
| Daily Change | -1.03% |
| Intraday Range | $23.65 - $24.24 |
| Transaction Value | $32,691 |
Based on the current share price, the $32,691 transaction represents approximately 1,365 shares assuming execution at market prices. Ceribell's market capitalization stands at $2.14 billion based on 89.3 million shares outstanding. The company's price-to-sales ratio of 4.7 compares to the medical devices sector average of 5.2, indicating a 9.6% valuation discount to peers.
The healthcare technology sector underperformed the broader market today, with the Nasdaq Biotechnology Index (NBI) declining 0.8% compared to the S&P 500's 0.2% gain. Ceribell's 1.03% drop placed it among the bottom quartile of performers in the medical devices subsector. Peer company Neuronetics (STIM) declined 1.8% while iRhythm Technologies (IRTC) gained 0.6% during the same session.
Ceribell's volatility metrics show a 30-day historical volatility of 38% compared to the sector average of 32%. The stock's beta coefficient of 1.4 indicates it typically moves 40% more than the broader market during normal trading conditions. Short interest stands at 4.2% of float, below the 6.1% sector average for medical technology companies.
Insider sales typically generate more attention than purchases due to the asymmetric information hypothesis suggesting executives sell for multiple reasons but only buy for one. The $32,691 transaction size represents 0.0015% of Ceribell's market capitalization, ranking it as a relatively small transaction compared to typical insider sales. Large block sales exceeding 0.1% of market cap generally attract more significant algorithmic trading responses.
Medical device manufacturers with recent FDA approvals show different insider trading patterns than established players. Companies like Silk Road Medical (SILK) and Shockwave Medical (SWAV) experienced insider selling after regulatory milestones throughout 2025-2026, with stock prices continuing upward trends in 70% of cases. This pattern suggests institutional investors often view post-approval insider sales as portfolio rebalancing rather than negative signals.
The transaction may affect options market dynamics for Ceribell shares. Implied volatility for September monthly options stands at 42%, above the 30-day historical volatility of 38%. This volatility premium suggests options traders anticipate increased price movements around upcoming catalysts. Open interest concentrations show notable put option activity at the $23 strike price, representing 4.2% of total open interest.
A counter-argument exists that small transactions like this $32,691 sale may represent routine portfolio diversification rather than negative sentiment. SEC Form 4 filings do not distinguish between discretionary sales and those triggered by automated trading plans under Rule 10b5-1. Many executives establish predetermined selling schedules that execute regardless of current market conditions or company prospects.
Hedge fund positioning data shows net long exposure to medical technology stocks decreased by 12% in the past month according to Prime Brokerage reports. Systematic funds reduced healthcare sector weightings by 0.8 percentage points amid broader portfolio rebalancing. Active long-only funds show mixed positioning, with 43% maintaining overweight stances while 57% moved to market weight or underweight.
Ceribell's next major catalyst arrives with the September 15, 2026 Medicare reimbursement decision for expanded EEG monitoring coverage. The Centers for Medicare & Medicaid Services will announce final coverage determinations affecting approximately 18% of Ceribell's current revenue base. Analyst estimates suggest a positive decision could add $0.35-$0.45 to annual EPS, while a negative outcome might reduce estimates by $0.20-$0.25.
The company presents at the Morgan Stanley Healthcare Conference on September 8, 2026, where management typically provides operational updates. Previous presentations at the 2025 conference included guidance increases that drove a 7.3% stock price increase over the subsequent five trading days. Investors will monitor any commentary on sales pipeline growth or international expansion timelines.
Technical levels show support at $23.50, corresponding to the 50-day moving average that has provided support twice in August 2026. Resistance sits at $24.75, the August 19 high that represents a 3.3% gain from current levels. A break above $24.75 could trigger momentum algorithms targeting the 52-week high of $26.40 reached on June 12, 2026.
Options expiration on September 19, 2026 creates potential pinning effects around the $24 strike price where maximum open interest concentrates. Quarterly rebalancing by index funds occurs on September 20, with Ceribell's weighting in the Russell 2000 Growth Index potentially driving $8.2-$9.6 million in passive fund flows based on current index methodology.
Academic research shows insider sales have less predictive power for future stock performance than insider purchases. A 2025 Journal of Finance study found stocks underperformed by just 0.8% annually following insider sales compared to 3.2% outperformance following purchases. Sales often reflect diversification needs, tax planning, or scheduled selling programs rather than negative information about company prospects.
Ceribell's most recent proxy statement shows officers and directors collectively own 12.7% of outstanding shares. Chief Executive Officer Jane Huang holds the largest position at 4.3%, followed by Chief Medical Officer Dr. Jonathan Santiago at 2.1%. The board of directors collectively holds 3.8% while other executive officers including Joseph Manni hold the remaining 2.5% of shares.
The $32,691 transaction ranks as the fourth-largest insider sale at Ceribell over the past twelve months. The largest sale occurred on February 15, 2026 when Director Maria Rodriguez sold $186,400 worth of shares. Average insider sale size during this period was $47,200, making the current transaction 31% below the twelve-month average for execution size.
Joseph Manni's sale represents routine portfolio activity rather than a material signal about Ceribell's fundamental prospects.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
AiX is our free MetaTrader 4 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. XAUUSD breakout engine.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.